Section Arrow
Quote
TLX.NASDAQ
- Telix Pharmaceuticals Ltd.
Quotes are at least 15-min delayed:2025/07/21 07:02 EDT
Pre Market
Last
 --
-- (--)
Bid
15.11
Ask
16.2
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 16.23
+0.09 (+0.56%)
Day High 
16.43 
Prev. Close
16.14 
1-M High
17.25 
Volume 
13.13K 
Bid
15.11
Ask
16.2
Day Low
15.8 
Open
16.43 
1-M Low
15.42 
Market Cap 
5.40B 
Currency USD 
P/E 165.98 
%Yield -- 
10-SMA 15.91 
20-SMA 16.15 
50-SMA 16.58 
52-W High 30.36 
52-W Low 13.61 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.14/1.72
Enterprise Value
5.96B
Balance Sheet
Book Value Per Share
1.11
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
783.21M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.03 -0.25 -10.96%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.075 -1 -7.10%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0475 -0.0002 -0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.18 +0.34 +5.82%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.18 +0.26 +4.39%
Quotes are at least 15-min delayed：2025/07/21 07:02 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.